Lu-PSMA and Stereotactic Radiotherapy Versus Radiotherapy Alone for Prostate Cancer (LUST) (LUST)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT05893381 |
Recruitment Status :
Recruiting
First Posted : June 7, 2023
Last Update Posted : November 18, 2023
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Prostate Cancer | Drug: [177Lu]Lu-PSMA I&T Radiation: Stereotactic Radiotherapy | Phase 2 |
Biochemical recurrence (BCR), i.e. prostate-specific antigen (PSA) only recurrence occurs in nearly one-third of patients, after primary definitive therapy for prostate cancer.
PSMA (prostate-specific membrane antigen) is an attractive target for diagnosis and therapy of metastasized prostate cancer (PCa) as its expression levels are directly correlated with androgen independence, metastases and progression.
Positron Emission Tomography/Computed Tomography (PET-CT) using PSMA is able to detect > 50% of relapses with PSA between 0.50 and 1 ng/mL and >75% with PSA between 1 and 2.
Oligometastatic prostate cancer include 1-3 asypmtomatic metastatic lesion(s) of the soft tissue or bone. The treatment of oligometastatic disease depends on multiple factors including the site, the size, number and location of metastases, and the effectiveness of treatments.
Recent advances in radiation therapy allow to image and treat precisely target lesions within any anatomic region of the body. Stereotactic radiation therapy permit highly conformal and precisely targeted radiation administered in a dose intensive strategy. Local control in excess of 75% has been reported for metastatic prostate cancer with very low toxicity.
Lutetium 177-PSMA (177Lu-PSMA) is the most extensively investigated PSMA radioligand for radionuclide therapy in castration resistant prostate cancer (CRPC). Several retrospective studies and three phase II prospective studies demonstrated safety and impressive efficacy of 177Lu-PSMA in metastatic CRPC (mCRPC).The purpose of this study is to evaluate in a randomized phase II study the impact of Lu-PSMA added to stereotactic radiotherapy vs radiotherapy alone in PSMA detected- metastatic lesions of hormone-sensible prostate cancer.
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 70 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | A Phase II Randomized Trial of Lu-PSMA and Stereotactic Radiotherapy Versus Radiotherapy Alone for Oligometastatic Prostate Cancer (LUST) |
Actual Study Start Date : | June 27, 2023 |
Estimated Primary Completion Date : | September 2025 |
Estimated Study Completion Date : | April 2028 |
Arm | Intervention/treatment |
---|---|
Experimental: Stereotactic Radiotherapy followed by Lu-PSMA (arm A)
Ablative stereotactic radiation on the metastatic sites. Delivered in a 1 to 5 fractions regimen. 177Lu-PSMA-I&T in 2 cycles of treatment at 6-8 weekly intervals at a dosage of 7.4 Gigabecquerel (GBq)
|
Drug: [177Lu]Lu-PSMA I&T
The radiopharmaceutical 177Lu-PSMA-I&T will be administered, by slow intravenous injection, in 2 cycles of treatment at 6-8 weekly intervals at a dosage of 7.4 GBq.
Other Name: 177Lu-PSMA Radiation: Stereotactic Radiotherapy Ablative stereotactic radiation on the metastatic sites. Delivered in a 1 to 5 fractions regimen, depending on the target size and the surrounding normal tissue constraints,
Other Name: Ablative stereotactic radiation |
Active Comparator: Stereotactic Radiotherapy (arm B)
Ablative stereotactic radiation on the metastatic sites. Delivered in a 1 to 5 fractions regimen.
|
Radiation: Stereotactic Radiotherapy
Ablative stereotactic radiation on the metastatic sites. Delivered in a 1 to 5 fractions regimen, depending on the target size and the surrounding normal tissue constraints,
Other Name: Ablative stereotactic radiation |
- 12-month PSA (Prostate-Specific Antigen)-progression-free survival (PSA-PFS) [ Time Frame: 12-months ]To determine the proportion of men with oligometastatic hormone sensitive prostate cancer who have PSA progressed after 12 months from randomization to Stereotactic Radiotherapy and Lu-PSMA versus Radiotherapy alone.
- 12-month radiographic Progression-free survival (rPFS), Androgen Deprivation Therapy-Free survival (ADT-FS) and Total progression-free survival (PSA-PFS+rPFS) [ Time Frame: 12-months ]To assess radiographic progression free survival (PFS) after 12 months, ADT free survival (ADT-FS) and Total progression-free survival (PSA-PFS+rPFS) of Lu-PSMA + Stereotactic Radiotherapy vs Stereotactic Radiotherapy defined as the time interval between the day of randomization and the day of disease progression.
- Incidence of Treatment-Emergent Adverse Events [Toxicity] [ Time Frame: 60 months ]To describe the toxicity of Lu-PSMA + Stereotactic Radiotherapy vs Stereotactic Radiotherapy for the population enrolled using Common Terminology Criteria for Adverse Events (CTCAE) version 5.0.
- Overall survival (OS) [ Time Frame: 60 months ]To assess overall survival (OS) defined as the time interval between the day of randomization and death or last contact.
- Proportion of subjects with undetectable PSA (<0.2 ng/mL) [ Time Frame: 60 months ]To assess proportion of subjects with undetectable PSA (<0.2 ng/mL) defined as a PSA level ≤0.20 ng/mL as measured during routine follow-up
- Quality of life questionnaire (QLQ) [ Time Frame: 60 months ]To assess quality of life in the Lu-PSMA+ Stereotactic Radiotherapy arm vs Stereotactic Radiotherapy only arm using the Brief Pain Inventory form. The scale ranging from 0-10, where 0 is labeled 'No pain,' and 10 is labeled 'Worst pain imaginable'.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | Male |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Patients with prostate cancer must have 1-3 asymptomatic metastatic lesions that are ≤ 5.0 cm or < 250 cm3 documented at CT/MRI or WBD-MRI.
- PSMA-PET/CT positive scan matching with lesions documented on baseline CT/MRI or WBD-MRI.
- Patients must have had their primary tumor treated with surgery and/or radiation and previous salvage radiation to the prostate bed or pelvis is allowed.
- Patients will be admitted to the therapeutic phase only if diagnostic PET/CT PSMA SUV max is ≥ 3.
- Histologic confirmation of malignancy (primary or metastatic tumor).
- Prostate specific antigen (PSA) ≥ 0.2 ng/mL but ≤ 50 ng/mL and Testosterone ≥ 125 ng/dL.
- PSA doubling time (PSADT) < 15 months. PSADT will be calculated using as many PSA values that are available from time of relapse (PSA > 0.2 ng/dL).
- Patients unfit or refusing ADT.
- Patients may have had prior systemic therapy and/or ADT associated with treatment of their primary prostate cancer. Patients may have had ADT associated with salvage radiation therapy.
- Patients must be ≥ 18 years of age.
- Patient understands the purpose of the study and the procedures required for it; the patient is willing to participate in the study and to sign a written informed consent document.
- Patients must have an Eastern Cooperative Oncology Group performance status ≤ 2.
- Patients should have a life expectancy of at least 6 months.
-
Patients must have normal organ and marrow function as defined as:
- Leukocytes >2,000/μL;
- Absolute neutrophil count >1,000/μL;
- Platelets >75,000/μL;
- total bilirubin within normal institutional limits (this will not apply to patients with confirmed Gilbert's syndrome);
- AST(SGOT)/ALT(SGPT) <2.5 X institutional upper limit of normal;
- Creatinine within normal institutional limits.
- If the participant engages in sexual activity with a woman of childbearing potential, a condom must be used together with another highly effective method of contraception during the Treatment Period and for 6 months after the last dose of study intervention. The participant must agree not to donate sperm for the purpose of reproduction during the Treatment Phase and for a minimum of 6 months after receiving the last dose of study intervention.
- Highly effective birth control methods are required beginning at the screening visit and continuing until 6 months following last treatment with study drug. Patients and female partner who is of childbearing potential must use 2 acceptable methods of birth control (1 of which must include a condom as a barrier method of contraception, see Appendix F) starting at screening and continuing throughout the study period and for 6 months after final study drug administration. Two acceptable methods of birth control thus include Condom (barrier method of contraception) and one of the following is required ( established use of oral, or injected or implanted hormonal method of contraception by the female partner; placement of an intrauterine device (IUD) or intrauterine system (IUS) by the female partner; additional barrier method like occlusive cap with spermicidal foam/gel/film/cream/suppository in the female partner; tubal ligation in the female partner; vasectomy or other procedure resulting in infertility (eg., bilateral orchiectomy), for more than 6 months.
16. Highly effective birth control methods are required beginning at the screening visit and continuing until 6 months following last treatment with study drug. Patients and female partner who is of childbearing potential must use 2 acceptable methods of birth control (1 of which must include a condom as a barrier method of contraception, starting at screening and continuing throughout the study period and for 6 months after final study drug administration.
Exclusion Criteria:
The participant may not enter the study if ANY of the following apply:
- No more than 3 years of ADT is allowed, with the most recent ADT treatment having occurred more than 6 months prior to enrollment.
- PSMA -PET/CT scan more than 3 months.
- Spinal cord compression or impending spinal cord compression.
- Suspected pulmonary and/or liver metastases.
- Bone metastasis in a femoral bone.
- Previous radiation therapy on the metastatic site.
- Patients who have had chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlier. A window of 3 days is permitted.
- Participation in another clinical trial with any investigational agents within 30 days prior to study screening. A window of 3 days is permitted.
- Any condition for which, in the opinion of the investigator, participation would not be in the best interest of the participant.
- Patients with known brain metastases should be excluded from this clinical trial because of their poor prognosis and because they often develop progressive neurologic dysfunction that would confound the evaluation of neurologic and other adverse events.
- History of allergic reactions attributed to compounds of similar chemical or biologic composition to 177-Lu-PSMA- I & T or other agents used in the study.
- Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
- Unable to lie flat during or tolerable SABR.
- Other known malignant neoplastic diseases in the patient's medical history with a disease-free interval of less than 3 years (except for previously treated basal cell carcinoma);
- Known HIV-positivity, whether or not symptomatic.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05893381
Contact: Oriana Nanni | +390543739266 | oriana.nanni@irst.emr.it | |
Contact: Bernadette Vertogen | +390544286058 | bernadette.vertogen@irst.emr.it |
Italy | |
UO Medicina Nucleare, AUSL della Romagna | Recruiting |
Cesena, FC, Italy, 47521 | |
Contact: Michela Casi michela.casi@auslromagna.it | |
UO Medicina Nucleare, IRCCS IRST | Recruiting |
Meldola, FC, Italy, 47014 | |
Contact: Federica Matteucci +39 0543739339 federica.matteucci@irst.emr.it |
Principal Investigator: | Federica Matteucci | UO Medicina Nucleare, IRCCS IRST |
Responsible Party: | Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori |
ClinicalTrials.gov Identifier: | NCT05893381 |
Other Study ID Numbers: |
IRST185.09 |
First Posted: | June 7, 2023 Key Record Dates |
Last Update Posted: | November 18, 2023 |
Last Verified: | November 2023 |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
PSMA PET/CT positive |
Prostatic Neoplasms Genital Neoplasms, Male Urogenital Neoplasms Neoplasms by Site Neoplasms |
Genital Diseases, Male Genital Diseases Urogenital Diseases Prostatic Diseases Male Urogenital Diseases |